Piramal Pharma Limited (NSE:PPLPHARMA)

Piramal Pharma Statistics

Total Valuation

Piramal Pharma has a market cap or net worth of INR 238.81 billion. The enterprise value is 282.01 billion.

Market Cap	238.81B
Enterprise Value	282.01B

Important Dates

The last earnings date was Tuesday, April 28, 2026.

Earnings Date	Apr 28, 2026
Ex-Dividend Date	Jul 16, 2025

Share Statistics

Piramal Pharma has 1.33 billion shares outstanding. The number of shares has decreased by -0.43% in one year.

Current Share Class	1.33B
Shares Outstanding	1.33B
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	-4.71%
Owned by Insiders (%)	0.19%
Owned by Institutions (%)	24.13%
Float	611.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	130.08
PS Ratio	2.69
PB Ratio	2.93
P/TBV Ratio	5.94
P/FCF Ratio	31.32
P/OCF Ratio	14.45
PEG Ratio	1.16

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.81, with an EV/FCF ratio of 36.98.

EV / Earnings	-86.52
EV / Sales	3.18
EV / EBITDA	28.81
EV / EBIT	191.09
EV / FCF	36.98

Financial Position

The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.70.

Current Ratio	1.51
Quick Ratio	0.74
Debt / Equity	0.70
Debt / EBITDA	6.16
Debt / FCF	7.44
Interest Coverage	0.27

Financial Efficiency

Return on equity (ROE) is -4.00% and return on invested capital (ROIC) is 0.73%.

Return on Equity (ROE)	-4.00%
Return on Assets (ROA)	0.34%
Return on Invested Capital (ROIC)	0.73%
Return on Capital Employed (ROCE)	0.68%
Weighted Average Cost of Capital (WACC)	5.98%
Revenue Per Employee	16.20M
Profits Per Employee	-595,215
Employee Count	5,476
Asset Turnover	0.53
Inventory Turnover	1.20

Taxes

In the past 12 months, Piramal Pharma has paid 1.50 billion in taxes.

Income Tax	1.50B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.37% in the last 52 weeks. The beta is 0.37, so Piramal Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	-11.37%
50-Day Moving Average	152.14
200-Day Moving Average	177.06
Relative Strength Index (RSI)	72.98
Average Volume (20 Days)	9,656,361

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Piramal Pharma had revenue of INR 88.69 billion and -3.26 billion in losses. Loss per share was -2.46.

Revenue	88.69B
Gross Profit	56.31B
Operating Income	903.80M
Pretax Income	-1.76B
Net Income	-3.26B
EBITDA	8.75B
EBIT	903.80M
Loss Per Share	-2.46

Balance Sheet

The company has 13.55 billion in cash and 56.75 billion in debt, with a net cash position of -43.19 billion or -32.53 per share.

Cash & Cash Equivalents	13.55B
Total Debt	56.75B
Net Cash	-43.19B
Net Cash Per Share	-32.53
Equity (Book Value)	81.63B
Book Value Per Share	64.78
Working Capital	24.33B

Cash Flow

In the last 12 months, operating cash flow was 16.53 billion and capital expenditures -8.90 billion, giving a free cash flow of 7.63 billion.

Operating Cash Flow	16.53B
Capital Expenditures	-8.90B
Depreciation & Amortization	7.84B
Net Borrowing	2.83B
Free Cash Flow	7.63B
FCF Per Share	5.74

Margins

Gross margin is 63.49%, with operating and profit margins of 1.02% and -3.68%.

Gross Margin	63.49%
Operating Margin	1.02%
Pretax Margin	-1.99%
Profit Margin	-3.68%
EBITDA Margin	9.86%
EBIT Margin	1.02%
FCF Margin	8.60%

Dividends & Yields

This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.08%.

Dividend Per Share	0.14
Dividend Yield	0.08%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	n/a
Buyback Yield	0.43%
Shareholder Yield	0.51%
Earnings Yield	-1.36%
FCF Yield	3.19%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4